These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. The established and future biomarkers of malignant pleural mesothelioma. Panou V; Vyberg M; Weinreich UM; Meristoudis C; Falkmer UG; Røe OD Cancer Treat Rev; 2015 Jun; 41(6):486-95. PubMed ID: 25979846 [TBL] [Abstract][Full Text] [Related]
23. Determination of Mesothelin Levels in Pleural Effusion Does Not Help Predict Survival of Patients With Malignant Pleural Mesothelioma. Fontana V; Pistillo MP; Vigani A; Canessa PA; Berisso G; Giannoni U; Ferro P; Franceschini MC; Carosio R; Tonarelli M; Rossi C; Dessanti P; Roncella S Anticancer Res; 2019 Sep; 39(9):5219-5223. PubMed ID: 31519636 [TBL] [Abstract][Full Text] [Related]
24. Serum biomarkers in patients with mesothelioma and pleural plaques and healthy subjects exposed to naturally occurring asbestos. Bayram M; Dongel I; Akbaş A; Benli I; Akkoyunlu ME; Bakan ND Lung; 2014 Feb; 192(1):197-203. PubMed ID: 24170217 [TBL] [Abstract][Full Text] [Related]
25. Newly established ELISA for N-ERC/mesothelin improves diagnostic accuracy in patients with suspected pleural mesothelioma. Sato T; Suzuki Y; Mori T; Maeda M; Abe M; Hino O; Takahashi K Cancer Med; 2014 Oct; 3(5):1377-84. PubMed ID: 25045139 [TBL] [Abstract][Full Text] [Related]
26. Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA. Henderson DW; Reid G; Kao SC; van Zandwijk N; Klebe S J Clin Pathol; 2013 Oct; 66(10):854-61. PubMed ID: 23833051 [TBL] [Abstract][Full Text] [Related]
27. Molecular pathways and diagnosis in malignant mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group. Chapel DB; Churg A; Santoni-Rugiu E; Tsujimura T; Hiroshima K; Husain AN Lung Cancer; 2019 Jan; 127():69-75. PubMed ID: 30642555 [TBL] [Abstract][Full Text] [Related]
28. Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis. Cui A; Jin XG; Zhai K; Tong ZH; Shi HZ BMJ Open; 2014 Feb; 4(2):e004145. PubMed ID: 24566531 [TBL] [Abstract][Full Text] [Related]
29. Prognostic role of osteopontin expression in malignant pleural mesothelioma. Cappia S; Righi L; Mirabelli D; Ceppi P; Bacillo E; Ardissone F; Molinaro L; Scagliotti GV; Papotti M Am J Clin Pathol; 2008 Jul; 130(1):58-64. PubMed ID: 18550471 [TBL] [Abstract][Full Text] [Related]
30. Tumoral CD10 expression correlates with aggressive histology and prognosis in patients with malignant pleural mesothelioma. Kadota K; Villena-Vargas J; Nitadori J; Sima CS; Jones DR; Travis WD; Adusumilli PS Ann Surg Oncol; 2015 Sep; 22(9):3136-43. PubMed ID: 25608772 [TBL] [Abstract][Full Text] [Related]
31. Clinical utility of diagnostic biomarkers in malignant pleural mesothelioma: a systematic review and meta-analysis. Schillebeeckx E; van Meerbeeck JP; Lamote K Eur Respir Rev; 2021 Dec; 30(162):. PubMed ID: 34789461 [TBL] [Abstract][Full Text] [Related]
32. Serum mesothelin, osteopontin and vimentin: useful markers for clinical monitoring of malignant pleural mesothelioma. Bonotti A; Simonini S; Pantani E; Giusti L; Donadio E; Mazzoni MR; Chella A; Marconi L; Ambrosino N; Lucchi M; Mussi A; Cristaudo A; Foddis R Int J Biol Markers; 2017 Mar; 32(1):e126-e131. PubMed ID: 27646775 [TBL] [Abstract][Full Text] [Related]
33. Malignant pleural mesothelioma: an update on biomarkers and treatment. Ray M; Kindler HL Chest; 2009 Sep; 136(3):888-896. PubMed ID: 19736192 [TBL] [Abstract][Full Text] [Related]
34. A prospective study to investigate the role of serial serum mesothelin in monitoring mesothelioma. de Fonseka D; Arnold DT; Stadon L; Morley A; Keenan E; Darby M; Armstrong L; Virgo P; Maskell NA BMC Cancer; 2018 Feb; 18(1):199. PubMed ID: 29454314 [TBL] [Abstract][Full Text] [Related]
36. Improved diagnosis and prognostication of patients with pleural malignant mesothelioma using biomarkers in pleural effusions and peripheral blood samples - a short report. Beije N; Kraan J; den Bakker MA; Maat APWM; van der Leest C; Cornelissen R; Van NM; Martens JWM; Aerts JGJV; Sleijfer S Cell Oncol (Dordr); 2017 Oct; 40(5):511-519. PubMed ID: 28577209 [TBL] [Abstract][Full Text] [Related]
38. Mesothelin and osteopontin. Hillerdal G Eur Respir J; 2013 Aug; 42(2):557. PubMed ID: 23904555 [No Abstract] [Full Text] [Related]
39. The use of pleural fluid sCD44v6/std ratio for distinguishing mesothelioma from other pleural malignancies. Porcel JM; Esquerda A; Rodriguez-Panadero F; Martínez-Iribarren A; Bielsa S J Thorac Oncol; 2011 Jan; 6(1):190-4. PubMed ID: 21079519 [TBL] [Abstract][Full Text] [Related]
40. Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology. Canessa PA; Franceschini MC; Ferro P; Battolla E; Dessanti P; Manta C; Sivori M; Pezzi R; Fontana V; Fedeli F; Pistillo MP; Roncella S Cancer Invest; 2013 Jan; 31(1):43-50. PubMed ID: 23249166 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]